Paraganglioma

Paraganglioma is a rare tumor that grows from special nerve-related cells called paraganglia. These cells sit beside blood vessels and nerves throughout the body. They are part of the autonomic nervous system, which controls things you do not think about, like blood pressure and breathing. Some paragangliomas make stress hormones called catecholamines (adrenaline, noradrenaline, dopamine). These are called functional tumors. Others do not make hormones; these are non-functional tumors. Paragangliomas can occur in the head and neck, chest, abdomen, or pelvis. A related tumor inside the adrenal gland is called pheochromocytoma. Paragangliomas can be single or multiple. Many are linked to inherited gene changes. Doctors treat them based on size, location, hormones, symptoms, and whether the tumor has spread. Any paraganglioma can behave aggressively; true “malignancy” is defined by metastasis (spread to lymph nodes or distant organs), not by how it looks under the microscope.

Paragangliomas (PGLs) are rare tumors that grow from the body’s neuroendocrine “paraganglia,” tiny clusters of nerve-like cells that sit alongside major blood vessels and nerves from the skull base to the pelvis. Some PGLs make too much adrenaline-type hormones (catecholamines), which can cause high blood pressure, headaches, palpitations, sweating, anxiety, and sudden spikes in blood pressure. PGLs are closely related to adrenal pheochromocytomas; together they’re called PPGL. Modern classifications group adrenal pheochromocytomas as “adrenal paragangliomas,” and extra-adrenal tumors as “extra-adrenal paragangliomas.” Up to 30–40% are linked to inherited gene changes (for example SDHx genes), so genetic counseling and lifelong follow-up are standard parts of care. MDPI+2OUP Academic+2

---

Other names

Paraganglioma is also called:

• Extra-adrenal pheochromocytoma (when it makes catecholamines outside the adrenal gland).

• Head and neck paraganglioma (for tumors in the ear, skull base, or neck).

• Carotid body tumor (when it grows at the carotid artery bifurcation).

• Glomus tumor (older term used for jugulotympanic and vagal lesions).

• Chemodectoma (older term, especially for carotid body tumors).

• Jugulotympanic paraganglioma (in the middle ear and jugular bulb).

• Vagal paraganglioma (along the vagus nerve).

• Sympathetic paraganglioma (in chest, abdomen, pelvis; often hormone-secreting).

These different names reflect where the tumor starts and whether it secretes hormones.

---

Types

By location

• Head and neck (parasympathetic) paraganglioma. Often in the carotid body, jugular bulb, middle ear, or vagus nerve. These usually do not make hormones and present with a neck mass, ear fullness, pulsating sound, or voice change.

• Thoracic, abdominal, or pelvic (sympathetic) paraganglioma. Often along the sympathetic chain, near the aorta, organ of Zuckerkandl, bladder wall, or uterus/prostate region. These are more likely to secrete catecholamines and cause high blood pressure and spells.

By function

• Functional. Secretes catecholamines (adrenaline, noradrenaline, dopamine). Causes spells of headache, sweating, palpitations, tremor, and high blood pressure.

• Non-functional. No hormone excess. Symptoms come from mass effect (pressure on nearby structures).

By inheritance

• Hereditary. Due to a germline (inherited) gene variant. Often multiple tumors, earlier age, and higher risk of spread in some genes (for example SDHB).

• Sporadic. No detectable inherited variant; usually a single tumor at a later age.

By behavior

• Localized. Limited to the original site.

• Metastatic. Spread to lymph nodes, bone, liver, lung, or other sites. In paraganglioma, “malignant” means metastatic.

---

Causes

1. Inherited SDHB variant. SDHB is a gene in the mitochondrial energy pathway (succinate dehydrogenase complex). A harmful change raises risk of paraganglioma, often in the abdomen or pelvis, and has a higher chance of spread compared with some other genes.

2. Inherited SDHD variant. SDHD variants often cause multiple head-and-neck paragangliomas. Risk is highest when the variant is inherited from the father (due to imprinting).

3. Inherited SDHC variant. SDHC variants usually present with head-and-neck tumors and sometimes extra-adrenal sympathetic tumors.

4. Inherited SDHA variant. Less common but can cause paraganglioma and sometimes other tumors.

5. Inherited SDHAF2 (SDH5) variant. Rare cause; often multiple head-and-neck tumors at a young age.

6. VHL syndrome (VHL gene). von Hippel–Lindau disease increases risk of pheochromocytoma and paraganglioma along with other tumors (retinal, CNS, kidney).

7. MEN2 (RET gene). Multiple endocrine neoplasia type 2 is known for medullary thyroid cancer and pheochromocytoma, but extra-adrenal paragangliomas can occur.

8. Neurofibromatosis type 1 (NF1 gene). People with NF1 can develop catecholamine-secreting tumors, including paraganglioma, though pheochromocytoma is more typical.

9. MAX gene variants. MAX is a transcription factor partner of MYC; germline variants can predispose to paraganglioma/pheochromocytoma.

10. TMEM127 gene variants. Another susceptibility gene that raises risk of PPGLs.

11. FH gene variants. Fumarate hydratase–deficient tumors can include paraganglioma; FH is also linked to hereditary leiomyomatosis and renal cell cancer.

12. EPAS1 (HIF-2α) variants. Gain-of-function changes can drive catecholamine-producing tumors by mimicking low-oxygen signaling.

13. EGLN1/2 (PHD1/2) variants. These affect oxygen-sensing enzymes, stabilizing HIF pathways and promoting tumor growth.

14. MDH2 variants. A rare metabolic gene cause; affects mitochondrial malate dehydrogenase and energy signaling.

15. SLC25A11 variants. A mitochondrial carrier gene that can predispose to paraganglioma.

16. DLST variants. Part of the tricarboxylic acid (TCA) cycle; rare cause linked to PPGL predisposition.

17. Somatic (non-inherited) mutations in tumor cells. Even without a family variant, the tumor can acquire changes in SDHx or other pathways that allow growth.

18. Chronic hypoxia (long-term low oxygen). Living at very high altitude, cyanotic heart disease, or chronic lung disease can stimulate paraganglia and increase risk, especially of carotid body tumors.

19. Prior neck irradiation (rare association). Radiation exposure to the neck in childhood/young adulthood has been linked to higher head-and-neck tumor risk in general; it is a rare, possible contributor.

20. Age and sporadic chance. Many cases happen without a known cause, especially in middle age, likely from a mix of small genetic changes and life exposures.

---

Symptoms

1. High blood pressure (steady or in sudden spikes). Hormone-secreting tumors can cause very high readings or dangerous swings.

2. Pounding headaches. Often brief, severe, and may come in spells with other symptoms.

3. Fast or irregular heartbeat (palpitations). A racing heart often occurs during catecholamine surges.

4. Heavy sweating. A classic feature of adrenaline release; clothes can become wet quickly during an episode.

5. Pale skin or flushing. Blood vessels tighten or dilate due to hormones, changing skin color.

6. Tremor and anxiety. The body feels “on edge,” shaky, or panicky during hormone peaks.

7. Weight loss and heat intolerance. A constantly “revved up” metabolism can lower weight and make heat feel worse.

8. Chest pain or shortness of breath. Spikes in blood pressure and heart rate can stress the heart and lungs.

9. Abdominal, pelvic, or back pain. A growing mass can press on nearby organs or nerves.

10. Neck mass or swelling. Head-and-neck tumors can present as a slow-growing lump near the jaw angle or along the side of the neck.

11. Pulsatile tinnitus (whooshing sound). Jugulotympanic tumors in the middle ear can cause a rhythmic sound with the heartbeat.

12. Hearing loss or ear fullness. Pressure from a middle-ear paraganglioma can reduce hearing and cause discomfort.

13. Hoarseness or voice change. Vagal nerve tumors can affect vocal cord movement.

14. Difficulty swallowing. Pressure on the throat or cranial nerves can make swallowing hard or painful.

15. Episodes triggered by stress, surgery, childbirth, or certain drugs. Physical stress or medications (like some anesthetics, MAO inhibitors, or stimulants) can provoke dangerous hormone surges.

---

Diagnostic tests

A) Physical examination

1. Blood pressure check sitting and standing. Doctors look for high readings or big jumps when you stand. Sudden surges suggest a hormone-secreting tumor. Repeating measurements over time helps catch short spikes.

2. Neck, ear, and cranial nerve exam. For head-and-neck tumors, the doctor gently feels the neck for firm, mobile, or pulsatile masses, looks in the ear canal for a reddish, pulsating mass, and checks facial movement, voice strength, gag reflex, and shoulder shrug to see if cranial nerves are affected.

3. Heart and lung exam. A fast or irregular heartbeat, extra sounds, or signs of heart strain can point to catecholamine excess. Rapid breathing or wheeze may be present during episodes.

4. Abdominal and pelvic exam. The clinician presses gently to find tender or firm areas and looks for masses; this can guide which imaging test to order first.

B) Bedside or manual assessments

5. Orthostatic vital signs. Heart rate and blood pressure measured after lying down and then again after standing for 1–3 minutes. A marked rise in heart rate or blood pressure suggests catecholamine surges or volume depletion from long-standing hypertension.

6. Focused neurologic screen. Quick tests of facial symmetry, voice, swallowing, tongue movement, and shoulder elevation help detect cranial nerve involvement from head-and-neck paragangliomas.

7. Audiologic bedside checks. Whispered-voice test or tuning fork (Rinne/Weber) can hint at conductive hearing loss from a middle-ear mass, prompting full audiology and imaging.

8. Medication review challenge (history-based). Clinicians systematically review drugs that can provoke crises (MAO inhibitors, stimulants, decongestants). This “manual” checklist helps avoid false spikes before testing.

C) Laboratory and pathological tests

9. Plasma free metanephrines. This is a first-line blood test. Metanephrines are breakdown products of catecholamines. High levels strongly suggest a secreting paraganglioma or pheochromocytoma. The test is very sensitive; it should be done after resting quietly and with attention to drugs and diet that can interfere.

10. 24-hour urinary fractionated metanephrines and catecholamines. This test measures daily hormone production and helps confirm the diagnosis. It can also show dopamine excess in some tumors.

11. Plasma 3-methoxytyramine. An extra marker that helps detect dopamine-secreting tumors, which are more common in extra-adrenal paragangliomas.

12. Chromogranin A (CgA). A general neuroendocrine marker. It can support the diagnosis but is less specific and can be elevated by other conditions or medications like proton pump inhibitors.

13. Basic blood tests (CBC, CMP, TSH). These look for anemia, kidney or liver problems, and thyroid disease that may mimic symptoms or affect treatment choices.

14. Pathology with immunohistochemistry (post-surgery or biopsy). Under the microscope, paragangliomas show zellballen nests (chief cells) with supporting sustentacular cells that stain for S100. Tumor cells often stain for synaptophysin and chromogranin. SDHB immunostaining loss suggests an SDH-mutated tumor.

15. Genetic testing panel (germline). Because many patients carry an inherited variant, doctors often order a multi-gene panel (SDHx, VHL, RET, NF1, MAX, TMEM127, FH, EPAS1, EGLN1/2, MDH2, SLC25A11, DLST). Results guide surveillance, family testing, and long-term care.

16. Biochemical interference review. Caffeine, nicotine, tricyclic antidepressants, levodopa, decongestants, and stress can cause false positives. A deliberate review and repeat testing after stopping interfering agents can clarify borderline results.

D) Electrodiagnostic tests

17. ECG (electrocardiogram). Looks for fast rhythm, extra beats, strain patterns, or ischemia caused by catecholamine surges and severe hypertension. It is quick and helps triage urgent care if chest pain occurs.

18. Echocardiogram (cardiac ultrasound). Not always required, but useful if there is long-standing high blood pressure or chest symptoms. It checks heart muscle thickening (hypertrophy) and pumping function that can be affected by excess catecholamines.

E) Imaging tests

19. MRI. Often preferred for head-and-neck lesions and for children or pregnant patients to avoid radiation. Paragangliomas are typically bright on T2 sequences and enhance with contrast. MRI of the neck, skull base, chest, abdomen, and pelvis is chosen based on symptoms and biochemistry.

20. CT scan. Fast and widely available. CT shows size, location, relation to vessels and bones, and detects lymph nodes or organ involvement. It is very helpful for abdominal and pelvic tumors.

21. Functional imaging with ^68Ga-DOTATATE PET/CT (somatostatin receptor imaging). Many paragangliomas express somatostatin receptors. This scan is very sensitive for finding primary and metastatic disease, especially in SDHx-related tumors.

22. ^18F-FDG PET/CT. Shows tumor glucose uptake. It is particularly useful in SDHB-mutated and metastatic paragangliomas, which are often highly FDG-avid.

23. ^123I-MIBG scintigraphy (or SPECT/CT). Targets norepinephrine transporters. It helps locate catecholamine-secreting tumors and can identify candidates for MIBG-based therapy. Sensitivity varies with genotype and tumor site.

24. Targeted anatomical imaging (CTA/MRA of head and neck). CT angiography or MR angiography shows the classic “lyre sign” at the carotid bifurcation for carotid body tumors and defines vessel involvement, which is key for surgical planning.

Non-pharmacological treatments (therapies & other measures)

1. Multidisciplinary care & center expertise
   Seeing a team that includes endocrine surgery, anesthesia, cardiology, nuclear medicine, genetics, and radiation oncology improves planning and safety. Complex decisions (which scan, which drug, when to operate, or which systemic therapy) benefit from experienced teams and shared protocols. Purpose: fewer complications and better long-term outcomes. Mechanism: coordinated planning reduces peri-operative catecholamine crises and matches the right therapy to tumor biology. OUP Academic

2. Pre-operative alpha-blockade + high-salt/high-fluid loading
   Before surgery, doctors block alpha receptors (details below) and advise extra salt and fluids to expand blood volume. Purpose: prevents life-threatening blood pressure spikes during tumor handling and avoids dangerous low blood pressure after tumor removal. Mechanism: alpha-blockade relaxes vessels; salt/fluids fill the circulation so pressure stays stable. OUP Academic

3. Home blood pressure & heart-rate monitoring
   Regular home checks help track responses to alpha-blockers and spot warning signs early. Purpose: safer titration and better symptom control. Mechanism: frequent readings guide dose changes and timing of surgery. OUP Academic

4. Medical ID & emergency plan
   Wearing a medical ID card/bracelet stating “catecholamine-secreting tumor/PPGL,” current blockers, and emergency contacts helps emergency teams act quickly. Purpose: faster, safer care during crises. Mechanism: reduces delays and medication errors. OUP Academic

5. Trigger avoidance (certain drugs & activities)
   Avoid nasal decongestants, amphetamines, cocaine, and abrupt strenuous exertion that can trigger surges; discuss anesthesia plans early. Purpose: fewer hypertensive crises. Mechanism: avoiding adrenergic triggers reduces catecholamine spikes. OUP Academic

6. Genetic counseling & family testing
   Because many PPGLs are inherited, first-degree relatives may need testing and screening. Purpose: early detection prevents complications. Mechanism: genotype-guided surveillance (for example, SDHB carriers) tailors imaging and lab intervals. OUP Academic+1

7. Long-term surveillance
   After surgery, periodic plasma or urine metanephrines and imaging are needed for life, because tumors can recur or new ones can appear. Purpose: catch recurrence early. Mechanism: monitoring biochemical markers and scans at guideline intervals. OUP Academic

8. Exercise, nutrition, and weight management (cardio-oncology basics)
   Safe, supervised aerobic exercise and gradual strength work help blood pressure, fitness, and fatigue; diet focuses on whole foods, vegetables, fruits, whole grains, and lean proteins (DASH-like). Purpose: supports cardiovascular health and treatment tolerance. Mechanism: exercise and diet improve vascular function and reduce BP and metabolic strain. ASCO Publications+1

9. Sodium/potassium balance (dietary pattern)
   Maintain guideline-level sodium restriction outside of the brief high-salt pre-op window; favor potassium-rich foods (unless medically contraindicated). Purpose: supports steady blood pressure. Mechanism: potassium blunts sodium’s vascular effects and helps relax vessel walls. www.heart.org+1

10. Diabetes & thyroid review
    Catecholamine excess can worsen glucose control; somatostatin analogs can affect glucose and thyroid tests. Purpose: optimize comorbidities. Mechanism: medication adjustments reduce peri-operative risk. FDA Access Data

11. Psychological support & anxiety management
    Spells can feel frightening. CBT, breathing techniques, and counseling reduce distress and sympathetic arousal. Purpose: improve quality of life and possibly reduce trigger sensitivity. Mechanism: stress-response regulation. OUP Academic

12. Pregnancy planning
    PPGL in pregnancy is high-risk; pre-conception counseling and specialized obstetric care are essential. Purpose: reduce maternal/fetal complications. Mechanism: timing surgery and blockade around gestation with specialist input. OUP Academic

13. Radiation-safety education (after AZEDRA or PRRT)
    Patients receive instructions to limit exposure to others for a set period. Purpose: keep family and public exposures within legal limits. Mechanism: time-and-distance rules based on drug physics and label guidance. FDA Access Data+1

14. Kidney protection during radiopharmaceuticals
    Amino-acid infusions during Lu-177-DOTATATE help protect kidneys. Purpose: lower renal radiation dose. Mechanism: competitive inhibition of tubular reabsorption of the peptide. FDA Access Data

15. Fertility counseling
    Some therapies can impair fertility (e.g., belzutifan and certain chemotherapies). Purpose: allow sperm/egg preservation when appropriate. Mechanism: plan before therapy. FDA Access Data

16. Vaccination & infection prevention
    If receiving systemic therapy or radiation that can lower counts, follow standard vaccine schedules and infection-prevention advice. Purpose: reduce complications. Mechanism: evidence-based survivorship care principles. ASCO Publications

17. Pain and symptom clinic referral
    For head/neck PGL or metastatic disease, structured pain and symptom support improves function. Purpose: maintain daily activities. Mechanism: multimodal symptom control. ESMO

18. Bone health measures
    If therapy or reduced activity threatens bone density, ensure vitamin D adequacy and weight-bearing exercise as allowed. Purpose: prevent fractures. Mechanism: maintain bone remodeling balance. Office of Dietary Supplements

19. Clear peri-operative anesthesia plan
    Anesthesiologists familiar with PPGL plan invasive monitoring and stepwise control of BP/HR during surgery. Purpose: reduce intra-op crises. Mechanism: titrated vasodilators, volume, and short-acting agents. OUP Academic

20. Lifelong education
    Understanding warning signs (new severe headaches, chest pain, sudden sweating/palpitations, or very high BP) encourages early care-seeking. Purpose: avoid emergencies. Mechanism: prompt evaluation of recurrence or metastasis. OUP Academic

---

Drug treatments

Important: Drugs 1–9 are for pre-op/medical control of catecholamine effects; drugs 10–20 focus on tumor-directed therapy. Some are FDA-approved for PPGL; others are used off-label but supported by guidelines or clinical data. Always individualize with your specialist team.

1. Phenoxybenzamine – non-selective, irreversible alpha-blocker
   Use/Purpose: first-line pre-op BP control and symptom relief.
   How it works: blocks alpha receptors, relaxing arteries/veins.
   Dose/Time: typically started days–weeks before surgery, titrated by BP/HR.
   Key effects: orthostatic hypotension, fatigue, nasal congestion.
   Evidence/Label: long-standing standard for pheo/PGL prep. FDA Access Data+1

2. Doxazosin – selective alpha-1 blocker
   Use: alternative to phenoxybenzamine; often better tolerated.
   Dose: begin low (e.g., 1 mg daily) and titrate; monitor BP.
   Effects: dizziness, orthostasis. FDA Access Data

3. Prazosin – selective alpha-1 blocker (shorter acting)
   Use: fine-tunes daytime BP control or complements long-acting agents.
   Note: similar side-effect profile to other alpha-1 blockers. OUP Academic

4. Metyrosine (Demser) – catecholamine synthesis inhibitor
   Use: reduces catecholamine production when blockade alone isn’t enough or tumor is very active.
   Dose: divided oral dosing with careful titration.
   Effects: sedation, depression, extrapyramidal symptoms (rare); avoid in hypersensitivity. DailyMed+1

5. Short-acting beta-blockers (e.g., propranolol, metoprolol) – beta-blockers
   Use: control tachycardia only after alpha-blockade is established (to avoid unopposed alpha).
   Dose: individualized; monitor heart rate and BP.
   Effects: bradycardia, fatigue. OUP Academic

6. Calcium-channel blockers (e.g., nifedipine, nicardipine) – vasodilators
   Use: adjuncts or alternatives for BP spikes or when alpha-blockers aren’t tolerated.
   Dose: oral or IV depending on situation.
   Effects: edema, flushing, headache. OUP Academic

7. Iobenguane I-131 (AZEDRA) – targeted radiopharmaceutical
   Indication (FDA): unresectable, locally advanced or metastatic, iobenguane-avid PPGL needing systemic therapy (≥12 years).
   How it works: carries radioactive iodine directly into adrenergic tumor cells.
   Dose/Time: dosed per body weight/uptake with radiation-safety rules.
   Key risks: myelosuppression, BP changes, renal toxicity; monitor closely. FDA Access Data+2FDA Access Data+2

8. Lutetium-177 DOTATATE (LUTATHERA) – PRRT
   Indication: FDA-approved for SSTR-positive gastro-enteropancreatic NETs; used off-label for SSTR-positive PPGL in practice/guidelines.
   How it works: delivers beta radiation via a somatostatin analogue to receptor-positive tumors; amino-acid infusion protects kidneys.
   Risks: nausea (from amino acids), cytopenias, renal/secondary malignancy risks (rare). FDA Access Data+1

9. Somatostatin analogues (octreotide, lanreotide) – hormone-modulating
   Use: symptom control and potential antiproliferative effect in SSTR-positive disease; often combined with PRRT sequencing.
   Dose: octreotide (short-acting or LAR), lanreotide (monthly deep SC).
   Effects: gallstones, glucose shifts, GI upset. FDA Access Data+2FDA Access Data+2

10. Belzutifan (WELIREG) – HIF-2α inhibitor (FDA-approved for PPGL, May 14, 2025)
    Indication: adults/pediatrics ≥12 with locally advanced, unresectable, or metastatic PPGL.
    How it works: blocks HIF-2α, a key hypoxia pathway driver in PPGL biology.
    Common issues: anemia, fatigue, hypoxia risk; fertility warnings.
    Why it matters: first oral therapy specifically approved for PPGL. U.S. Food and Drug Administration+1

11. Temozolomide (± capecitabine “CAPTEM”) – alkylating chemotherapy
    Use: active especially in SDHB-mutated metastatic PPGL.
    Dose: cycles per label (temozolomide) with supportive care.
    Effects: myelosuppression, fatigue, nausea. (CAPTEM is off-label for PPGL; use in experienced centers.) FDA Access Data

12. Sunitinib – VEGF-targeted TKI
    Use: progressive metastatic PPGL in selected patients (off-label); data suggest disease control in some cases.
    Dose: per label schedules (e.g., 50 mg 4/2 or continuous lower dose).
    Effects: hypertension, fatigue, hand-foot syndrome, cytopenias. FDA Access Data

13. CVD regimen (cyclophosphamide + vincristine + dacarbazine) – cytotoxic chemo
    Use: legacy regimen for metastatic PPGL; responses in some patients.
    Key effects: myelosuppression, neuropathy (vincristine), nausea. (Off-label; specialist oversight required.) OUP Academic

14. Prazosin/terazosin add-ons – additional alpha-1 blockers
    Use: fine-tuning blood pressure alongside phenoxybenzamine or instead of it.
    Effects: similar to doxazosin. OUP Academic

15. Esmolol or labetalol (intra-operative/ICU settings) – short-acting beta blockade
    Use: rapid heart-rate control with careful alpha coverage.
    Note: labetalol’s alpha:beta ratio makes it less ideal for initial blockade; use only with expert protocols. OUP Academic

16. Nifedipine/nicardipine (IV for crises) – CCBs
    Use: control peri-operative BP spikes.
    Mechanism/Effects: arterial vasodilation; watch for hypotension. OUP Academic

17. Octreotide short-acting (pre-PRRT or symptom control)
    Use: verify receptor control and manage flushing/diarrhea if present.
    Effects: GI upset, gallstones. FDA Access Data

18. Lanreotide depot
    Use: monthly maintenance for SSTR-positive disease.
    Effects: as above; fertility considerations noted in label. FDA Access Data

19. Supportive growth-factor use (select cases)
    Use: when myelosuppression occurs from chemo or radionuclides, hematology may consider growth-factor support per oncology standards—not disease-directed therapy.
    Note: individualized and risk-balanced. ASCO Publications

20. Antiemetics, acid suppression, and other adjuncts
    Use: manage nausea, reflux, and treatment side effects to preserve nutrition and quality of life.
    Rationale: guideline-based supportive oncology. ASCO Publications

---

Dietary molecular supplements

Straight talk: No supplement shrinks a paraganglioma. Supplements may help correct deficiencies, support bone/muscle health, or help BP only as adjuncts. Always clear supplements with your care team (some interact with BP or cancer drugs).

1. Vitamin D (if deficient) – supports bone and immune function; typical replacement 600–2000 IU/day, individualized by levels; excess can harm (hypercalcemia). Mechanism: improves calcium handling and bone remodeling. Office of Dietary Supplements

2. Potassium (diet first; supplements only if advised) – higher potassium intake (dietary) helps lower BP by countering sodium’s effects; supplements require clinician approval, especially with kidney or certain heart drugs. Mechanism: vasodilation and natriuresis. www.heart.org

3. Magnesium (diet emphasis) – supports vascular tone and BP control; supplement only for documented deficiency (dose varies). Mechanism: smooth-muscle relaxation. PMC

4. Omega-3 fatty acids – diet rich in fish or clinician-guided supplements can support triglyceride/BP modestly; doses vary; watch for bleeding risk at higher doses. Mechanism: anti-inflammatory, endothelial effects. ASCO Publications

5. Calcium (if intake is low) – bone support when activity drops or on therapies affecting bone; avoid excess; dose individualized. Mechanism: skeletal mineral balance with vitamin D. Office of Dietary Supplements

6. Protein optimization (food-first, consider whey/plant blends if needed) – preserves muscle during treatment; dosing per dietitian. Mechanism: supports lean mass and recovery. ASCO Publications

7. Fiber (soluble/insoluble; psyllium if needed) – helps weight, lipids, and BP; titrate to avoid GI upset. Mechanism: gut-mediated metabolic benefits. Dietary Guidelines

8. Iodine caution – do not take iodine supplements unless your nuclear medicine doctor advises; free iodine can interfere with iobenguane therapy planning. Mechanism: competitive uptake effects. FDA Access Data

9. Amino-acid infusions with PRRT (clinical, not OTC) – given during Lu-177-DOTATATE to protect kidneys; not a home supplement. Mechanism: reduces renal tubular reabsorption of the peptide. FDA Access Data

10. General multivitamin (if diet is limited) – low-dose, no-iron unless deficient; avoid “mega-dose” products. Purpose: cover gaps without risky doses. Mechanism: micronutrient adequacy. Dietary Guidelines

---

Immunity booster / regenerative / stem-cell drugs

I can’t list or recommend any “immunity booster,” “regenerative,” or “stem-cell drugs” for paraganglioma—there are no FDA-approved stem-cell or regenerative medicines to treat PPGL, and promoting unapproved products would be unsafe and misleading. If you’re receiving chemo or radiopharmaceuticals, your oncology team may use standard supportive medicines (vaccines, growth-factor support, antimicrobials) when indicated—but those are not tumor-curing “immune boosters.” Safer alternatives include guideline-based vaccines, nutrition, exercise, sleep hygiene, and infection-prevention plans under your oncologist’s guidance. ASCO Publications

---

Surgeries (what is done and why)

1. Open en-bloc resection (extra-adrenal abdominal/pelvic PGL)
   For larger, invasive, or vascularly complex tumors, open surgery allows vascular control and complete removal. Goal: cure or maximal debulking while preventing intra-op surges. OUP Academic

2. Minimally invasive resection (selected lesions)
   Laparoscopic/retroperitoneoscopic approaches may be used in carefully chosen cases with expert teams. Goal: quicker recovery with equal oncologic control when feasible. OUP Academic

3. Head & neck PGL resection (skull base/neck)
   Performed with skull-base/ENT and vascular teams; decisions balance tumor control with nerve preservation; radiotherapy is often preferred for some HNPGLs. Goal: local control and symptom relief. ESMO

4. Metastasectomy (selected cases)
   Removal of limited metastases (e.g., liver, lung, bone) can reduce symptoms and tumor burden. Goal: symptom relief and potential progression delay. ESMO

5. Palliative procedures (embolization, nerve decompression)
   When cure isn’t possible, targeted procedures relieve pain/bleeding or protect function. Goal: quality-of-life improvement. ESMO

---

Preventions & practical safety tips

1. Genetic counseling/testing for patients and at-risk relatives (prevents late diagnosis). OUP Academic

2. Lifelong follow-up with labs/imaging per guideline schedule. OUP Academic

3. Avoid adrenergic triggers (decongestants, stimulants, cocaine); review all new meds. OUP Academic

4. Maintain healthy weight, exercise within plan, limit sodium, emphasize potassium-rich foods (unless contraindicated). AHA Journals+1

5. Have a written emergency plan and medical ID. OUP Academic

6. Manage glucose, thyroid, and lipids—optimize comorbid conditions. FDA Access Data

7. Pre-op alpha-blockade and volume expansion for any surgery or invasive procedure. OUP Academic

8. Radiation-safety compliance after AZEDRA/PRRT; follow all instructions. FDA Access Data+1

9. Fertility counseling before systemic therapy if family planning is important. FDA Access Data

10. Evidence-based survivorship care: vaccines, nutrition, physical activity. ASCO Publications

---

When to see a doctor urgently

• New or worsening severe headache with very high blood pressure, chest pain, shortness of breath, heavy sweating, or rapid irregular heartbeat.

• Fainting, vision changes, or neurological symptoms.

• After AZEDRA/PRRT: fever, uncontrolled nausea/vomiting, bleeding, severe fatigue, or shortness of breath.
  These can signal a hypertensive crisis, arrhythmia, bleeding, or treatment toxicities and require immediate evaluation. FDA Access Data+1

---

What to eat & what to avoid (simple list you can actually use)

Eat more of: vegetables, fruits, legumes, whole grains, nuts, seeds, fish; aim for potassium-rich choices (bananas, leafy greens, beans, yogurt) unless your clinician says otherwise. Keep protein adequate, focusing on food first. American Cancer Society+1

Limit/Avoid: excess sodium (restaurant/processed foods), added sugars, and heavy alcohol; avoid stimulant supplements and “energy” products. Do not take iodine supplements without nuclear-medicine clearance if you are being evaluated for AZEDRA. Dietary Guidelines+1

---

FAQs

1) Is paraganglioma cancer?
PGLs are tumors with variable behavior; some remain localized, while others spread (metastasize). All PPGLs have some malignant potential, so lifelong follow-up is advised. OUP Academic

2) What symptoms should make me suspicious?
High BP spikes, severe headaches, pounding heartbeat, sweating, anxiety spells—especially in bursts—should prompt testing for catecholamine excess. OUP Academic

3) How is it diagnosed?
By measuring plasma or urine metanephrines and using targeted imaging (CT/MRI; plus MIBG or somatostatin-receptor PET when indicated). OUP Academic

4) Do all PGLs make hormones?
No. Some are “non-secretory,” especially many head/neck PGLs, and are found because of a mass or on imaging. ESMO

5) Why is alpha-blockade started before beta-blockade?
Starting beta-blockers first can leave alpha receptors unopposed and trigger dangerous BP spikes; alpha comes first. OUP Academic

6) Can surgery cure me?
Often yes for localized tumors. But because new tumors can occur (especially with gene variants), long-term follow-up is essential. OUP Academic

7) What if the tumor has spread?
Options include AZEDRA (iobenguane I-131) for MIBG-avid disease, PRRT for SSTR-positive disease, belzutifan (now FDA-approved for PPGL), targeted therapy, and chemotherapy—chosen by a specialist team. FDA Access Data+2FDA Access Data+2

8) Is belzutifan really new for PPGL?
Yes. FDA approved belzutifan on May 14, 2025—the first oral therapy specifically for PPGL. U.S. Food and Drug Administration

9) Are somatostatin analogs chemo?
No. They are hormone-modulating medicines that can slow growth and improve symptoms when tumors express somatostatin receptors. FDA Access Data

10) Does PRRT work for PGL?
PRRT is FDA-approved for certain GI-pancreatic NETs; for PGL it’s off-label but used for SSTR-positive disease at experienced centers with growing evidence. FDA Access Data+1

11) Do supplements cure PGL?
No. They cannot shrink tumors. Use them only to correct deficiencies and support health with your team’s approval. Office of Dietary Supplements

12) Can I get pregnant with a history of PGL?
Many can, but planning with specialists is vital; uncontrolled catecholamine excess in pregnancy is dangerous. OUP Academic

13) Should my family be tested?
Often yes, because many PPGLs are inherited. A genetics consult will guide who, when, and how. OUP Academic

14) What diet pattern is safest long-term?
A heart-healthy, DASH-like pattern: low sodium, high in vegetables, fruits, whole grains, and lean proteins, with adequate potassium if safe for you. AHA Journals+1

15) How often will I need checkups after surgery?
For life—your team will set intervals for labs and imaging based on your risk and genetics. OUP Academic

Disclaimer: Each person’s journey is unique, treatment plan, life style, food habit, hormonal condition, immune system, chronic disease condition, geological location, weather and previous medical  history is also unique. So always seek the best advice from a qualified medical professional or health care provider before trying any treatments to ensure to find out the best plan for you. This guide is for general information and educational purposes only. Regular check-ups and awareness can help to manage and prevent complications associated with these diseases conditions. If you or someone are suffering from this disease condition bookmark this website or share with someone who might find it useful! Boost your knowledge and stay ahead in your health journey. We always try to ensure that the content is regularly updated to reflect the latest medical research and treatment options. Thank you for giving your valuable time to read the article.

The article is written by Team RxHarun and reviewed by the Rx Editorial Board Members

Last Updated: November 12, 2025.

PDF Documents For This Disease Condition References